Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions

Table 1 Baseline patient characteristics

No. of patients	n = 392
Gender (male/female)	159/233
Age, yr	71.0	(64.0-77.0)
< 65 yr vs ≥ 65 yr	99/293
Laboratory data
Level of viremia (log IU/mL)	6.2	(5.8-6.5)
< 6.0 vs ≥ 6.0	137 vs 255	(35.1% vs 64.9%)
Platelet count (× 104/mm3)	12.6	(9.2-16.7)
10 < vs ≥ 10	114/278	(29.0% vs 70.4%)
ALT (IU/L)	41	(29-65)
γ-GTP(IU/L)	34	(22-57)
Other data
Prior treatment
IFN vs PEG plus RBV vs TVR vs SMV	70/147/13/9
NS5A polymorphisms, n (%)
L31 substitution, n = 288	10 (3.5)
Y93 substitution, n = 321	27 (8.4)
L31 and/or Y93, n = 321	35 (10.9)

Data are presented as numbers. Percentages or medians with interquartile ranges are presented in parentheses. ALT: Alanine aminotransferase; γ-GTP: Gamma-glutamyltransferase; IFN: Interferon; PEG plus RBV: Pegylated interferon plus ribavirin; TVR: Pegylated interferon plus ribavirin plus telaprevir triple therapy; SMV: Pegylated interferon plus ribavirin plus simeprevir triple therapy; L31: NS5A: L31 substitution patients. A total of 288 patients were assessed at pretreatment; Y93: NS5A:Y93 substitutions. A total of 321 patients were assessed at pretreatment.